- BIOBUSINESS BRIEFS
Novel drug targets in 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 23, 330 (2024)
doi: https://doi.org/10.1038/d41573-024-00057-9
Acknowledgments
This article is part of a series from the NIH Common Fund Illuminating the Druggable Genome (IDG) programme. The goal of IDG is to catalyse research on understudied proteins from druggable gene families by providing reagents, phenotypes and a mineable database; focusing on GPCRs, kinases and ion channels. This work was funded by NIH grant U24 CA224370. For more information, see https://druggablegenome.net/
Competing Interests
T.I.O. is a full-time employee of Expert Systems Inc. He previously worked for Roivant Sciences Inc. and AstraZeneca R&D. The other authors declare no competing interests.